The cost‐effectiveness of NT‐proBNP for assessment of suspected acute heart failure in the emergency department

Author:

Walkley Ryan1,Allen A. Joy1,Cowie Martin R.2,Maconachie Ross3,Anderson Lisa4

Affiliation:

1. Roche Diagnostics UK and Ireland Burgess Hill UK

2. Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust and Faculty of Lifesciences and Medicine King's College London London UK

3. Value, Access and Devolved Nations, Merck Sharp and Dohme (UK) Ltd London UK

4. Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute St George's, University of London, St George's Hospital London UK

Abstract

AbstractAimsWhen relying on clinical assessment alone, an estimated 22% of acute heart failure (AHF) patients are missed, so clinical guidelines recommend the use of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) for AHF diagnosis. Since publication of these guidelines, there has been poor uptake of NT‐proBNP testing in part due to concerns over excessive false positive referrals resulting from the low specificity of a single ‘rule‐out’ threshold of <300 pg/mL. Low specificity can be mitigated by the addition of age‐specific ‘rule‐in’ NT‐proBNP thresholds.Methods and resultsA theoretical hybrid decision tree/semi‐Markov model was developed, combining global trial and audit data to evaluate the cost‐effectiveness of NT‐proBNP testing using age‐specific rule‐in/rule‐out (RI/RO) thresholds, compared with NT‐proBNP RO only and with clinical decision alone (CDA). Cost‐effectiveness was measured as the incremental cost per quality‐adjusted life year (QALY) gained and incremental net health benefit. In the base case, using UK‐specific inputs, NT‐proBNP RI/RO was associated with both greater QALYs and lower costs than CDA. At a willingness‐to‐pay threshold of £20 000/QALY, NT‐proBNP RO was also cost‐effective compared with CDA [incremental cost‐effectiveness ratio (ICER) of £8322/QALY], but not cost‐effective vs. RI/RO (ICER of £64 518/QALY). Overall, NT‐proBNP RI/RO was the most cost‐effective strategy. Sensitivity and scenario analyses were undertaken; the conclusions were not impacted by plausible variations in parameters, and similar conclusions were obtained for the Netherlands and Spain.ConclusionsAn NT‐proBNP strategy that combines an RO threshold with age‐specific RI thresholds provides a cost‐effective alternative to the currently recommended NT‐proBNP RO only strategy, achieving greater diagnostic specificity with minimal reduction in sensitivity and thus reducing unnecessary echocardiograms and hospital admissions.

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference26 articles.

1. European Heart Network (EHN).Heart failure and cardiovascular diseases—a European Heart Network paper.2019. Available from:https://ehnheart.org/publications‐and‐papers/publications/1202:heart‐failure‐and‐cardiovascular‐diseases.html. Accessed on: 27 January 2022.

2. National Institute for Health and Care Excellence (NICE).Acute heart failure: diagnosis and management (CG187).2014. Available from:https://www.nice.org.uk/guidance/cg187. Accessed on: 25 January 2022.

3. NHS Wales.Cardiovascular Atlas of Variation.2019. Available from:https://collaborative.nhs.wales/networks/wales‐cardiac‐network/cardiac‐network‐documents/cardiovascularatlasofvariation‐march2019‐pdf/. Accessed on: 27 January 2022.

4. British Heart Foundation (BHF).Heart failure: a blueprint for change.2020. Available from:https://www.bsh.org.uk/wp‐content/uploads/2020/10/Heart‐Failure‐A‐Blueprint‐For‐Change‐Oct‐2020‐3.pdf. Accessed on: 27 January 2022.

5. Health Technology Wales (HTW).Evidence appraisal report: natriuretic peptides to rule‐in and rule‐out a diagnosis of acute heart failure in adults in the emergency department setting.2021. Available from:https://healthtechnology.wales/wp‐content/uploads/2021/11/EAR026‐BNP‐and‐NTproBNP.pdf. Accessed on: 27 January 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3